Basit öğe kaydını göster

dc.contributor.authorAsa, Sylvia L.
dc.contributor.authorErbil, Yesim
dc.contributor.authorBozbora, Alp
dc.contributor.authorKapran, Yersu
dc.contributor.authorTascioglu, Cemil
dc.contributor.authorOzbey, Nese Colak
dc.date.accessioned2021-03-05T21:11:36Z
dc.date.available2021-03-05T21:11:36Z
dc.date.issued2009
dc.identifier.citationOzbey N. C. , Kapran Y., Bozbora A., Erbil Y., Tascioglu C., Asa S. L. , "Ectopic Growth Hormone-Releasing Hormone Secretion by a Neuroendocrine Tumor Causing Acromegaly: Long-Term Follow-Up Results", ENDOCRINE PATHOLOGY, cilt.20, ss.127-132, 2009
dc.identifier.issn1046-3976
dc.identifier.othervv_1032021
dc.identifier.otherav_d7b5f174-0e00-4d01-81f9-dc8a3b377ec3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/142331
dc.identifier.urihttps://doi.org/10.1007/s12022-009-9067-1
dc.description.abstractEctopic secretion of growth hormone-releasing-hormone (GHRH) is a rare cause of acromegaly-representing less than 1% of patients. A 25-year-old woman was admitted to the hospital with acromegaly and a 6 x 6 cm infrahepatic mass. Sellar magnetic resonance imaging indicated diffuse pituitary enlargement consistent with hyperplasia. The infrahepatic mass was resected, and the histopathological diagnosis was a well-differentiated invasive neuroendocrine carcinoma of the duodenum with metastases to local lymph nodes. The tumor cells contained cytoplasmic immunoreactivity for GHRH. Because increased IGF-1 concentrations persisted after the operation, the patient was treated with octreotide long-acting repeatable (LAR) injections of 20 mg/month. Growth hormone and IGF-1 levels normalized. After 6 years of surveillance, a left paraaortic mass was detected by uptake of indium(111) octreotide. Surgical exploration revealed metastatic neuroendocrine carcinoma in a 2.5-cm lymph node. Postoperatively, the IGF-1 concentration was mildly elevated. Octreotide LAR therapy is being continued at 10 mg/month. This case suggests that octreotide treatment may have a beneficial effect on disease course and can be maintained for as long as 7 years in a patient with acromegaly due to a GHRH-secreting neuroendocrine carcinoma.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectCerrahi Tıp Bilimleri
dc.subjectPatoloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectBiyokimya
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectBiyoloji ve Biyokimya
dc.subjectPATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleEctopic Growth Hormone-Releasing Hormone Secretion by a Neuroendocrine Tumor Causing Acromegaly: Long-Term Follow-Up Results
dc.typeMakale
dc.relation.journalENDOCRINE PATHOLOGY
dc.contributor.departmentUniversity Of Toronto , ,
dc.identifier.volume20
dc.identifier.issue2
dc.identifier.startpage127
dc.identifier.endpage132
dc.contributor.firstauthorID192486


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster